NUC-7738: Unlocking the Potential of Immunotherapy

The Importance of Modifying the TME in Cancer

The tumor microenvironment (TME) is a highly dynamic & interactive system that promotes tumor growth and metastasis.

The full potential of immunotherapy will only be achieved if this complex network is disrupted; therefore, perturbing cancer cells and modulating the TME represents an important therapeutic strategy.

Targeting individual components of the TME is insufficient. Due to the heterogenous nature of cancer, therapies that target multiple aspects of the TME are urgently needed.

NUC-7738 targets multiple aspects of the TME

NUC-7738 is a novel agent that disrupts RNA polyadenylation and profoundly impacts gene expression in cancer cells. This alters their interactions within the TME to shift the balance of probability away from cancer cell survival, thereby enhancing treatment efficacy.

NUC-7738 perturbs cancer cells & targets multiple aspects of the TME:

  • • Disrupting cancer cell metabolism
  • • Altering protein synthesis
  • • Reducing immune evasion

NUC-7738 has shown promising anti-cancer activity in the clinic, both as a single-agent and in combination with the PD-1 inhibitor pembrolizumab.

NUC-7738 plus pembrolizumab shows encouraging anti-cancer activity in PD-1 inhibitor resistant patients:

  • • Responses in PD-1 refractory and resistant patients and a compelling disease control rate
  • • Prolonged progression free survival (mPFS 5.4 months vs current SOC 2-3 months)
  • • Favorable safety profile

Clinical, translational & scientific data support multiple clinical development pathways for NUC-7738 across several tumor indications & treatment combinations.

Current Development Status

Clinical Data

NUC-7738 has shown promising anti-cancer activity in the clinic, both as a single-agent and in combination with pembrolizumab. Over 60 patients with advanced solid tumors have received NUC-7738:

NUC-7738 Publications

Clinical Presentations
Non-clinical Presentations
Papers